Kronos Bio (NASDAQ:KRON) Downgraded to “Hold” Rating by TD Cowen

TD Cowen lowered shares of Kronos Bio (NASDAQ:KRON) from a buy rating to a hold rating in a research report released on Thursday morning, Marketbeat Ratings reports.

Several other research firms also recently weighed in on KRON. HC Wainwright reiterated a “buy” rating and set a $2.25 price target on shares of Kronos Bio in a research note on Monday, August 19th. Piper Sandler reiterated an “overweight” rating and set a $6.00 price target on shares of Kronos Bio in a research note on Tuesday, October 8th.

Kronos Bio Stock Performance

Shares of NASDAQ:KRON opened at $0.85 on Thursday. Kronos Bio has a 1 year low of $0.69 and a 1 year high of $1.60. The business has a fifty day moving average price of $0.95 and a two-hundred day moving average price of $1.03.

Institutional Trading of Kronos Bio

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Kronos Bio by 14.6% during the 1st quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company’s stock worth $2,533,000 after purchasing an additional 247,918 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Kronos Bio by 17.2% during the 1st quarter. Acadian Asset Management LLC now owns 774,559 shares of the company’s stock worth $1,005,000 after purchasing an additional 113,618 shares in the last quarter. Forefront Analytics LLC lifted its holdings in Kronos Bio by 75.0% during the 2nd quarter. Forefront Analytics LLC now owns 134,998 shares of the company’s stock worth $167,000 after purchasing an additional 57,867 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Kronos Bio during the 1st quarter worth about $71,000. Hedge funds and other institutional investors own 64.09% of the company’s stock.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.